The first 29 amino acids of growth-hormone-releasing hormone — the fragment that carries the signalling activity. Below: what Sermorelin is, what it does in plain terms, and the published studies — for laboratory research use only.
- Class
- GHRH analog (1-29)
- Published studies cited
- 4
- Literature span
- 1999–2021
What Sermorelin is
Sermorelin is GHRH(1-29), a synthetic version of the biologically active fragment of growth-hormone-releasing hormone. Rather than supplying growth hormone itself, it acts one step upstream, at the pituitary receptor that triggers the body's own release. It has a genuine clinical history — it was developed and marketed as a pharmaceutical for diagnosing and managing growth-hormone deficiency before being discontinued commercially. It is supplied here as an analytical-grade reference material for in-vitro laboratory research only.
Where it comes from
Growth-hormone-releasing hormone was characterised in the early 1980s, and researchers quickly established that its full 44-amino-acid sequence was not required — the first 29 residues carried essentially all of the receptor activity. That truncated fragment became sermorelin, which was developed pharmaceutically and used clinically, notably as a diagnostic agent for probing whether a pituitary could respond at all.
What it does — in plain terms
It binds the pituitary GHRH receptor, where it has been shown to stimulate pulsatile release of endogenous growth hormone.
How it works
Sermorelin acts at the GHRH receptor on pituitary somatotroph cells. Binding there stimulates synthesis and release of growth hormone, which is why it has been used diagnostically: if the pituitary responds, the deficiency lies upstream in the hypothalamus rather than in the gland itself.
Because it works through the body's own release machinery, the resulting pattern is pulsatile and subject to normal feedback — somatostatin still restrains release, and IGF-1 feedback still applies. This is the mechanistic distinction most often drawn in the literature between a releasing-hormone analog and administering growth hormone directly.
Its half-life in circulation is short, measured in minutes, which shapes how it has been studied and is a practical consideration in any experimental design.
What the research shows
Sermorelin has better-quality evidence behind it than most compounds in this catalog, because it was developed as a pharmaceutical and studied in that setting. The clinical literature is real, particularly around growth-hormone deficiency in children and its use as a diagnostic. Claims that extend beyond that setting — into ageing or performance — are far less supported and rest largely on mechanistic reasoning rather than trial data.
- Clinical Interventions in Aging, 2006 — Reviewed the case for GHRH-analog signalling over direct growth-hormone administration, arguing that preserving pulsatility and feedback is mechanistically preferable.
- BioDrugs, 1999 — Reviewed its established use in diagnosing and managing idiopathic growth-hormone deficiency in children — the setting where the evidence is strongest.
- Drug Testing and Analysis, 2021 — An analytical-chemistry review of how synthetic GHRH analogs are detected and measured, relevant to reference-material work.
- Annals of Translational Medicine, 2021 — Exploratory work examining GHRH-receptor signalling in a tissue context outside the pituitary.
What Sermorelin is studied for
Diagnostic endocrinology. Its best-evidenced application: testing whether a pituitary can respond to a GHRH signal, distinguishing hypothalamic from pituitary causes of deficiency.
Paediatric growth-hormone deficiency. Reviewed clinical use in children with idiopathic deficiency, where it was studied as a pharmaceutical.
Analytical detection. Because GHRH analogs are of interest in anti-doping analysis, there is a methods literature on identifying them.
Storage & handling
As a lyophilized (freeze-dried) powder, sermorelin reference material is most stable kept cold and dark — refrigerated for short-term storage, frozen for longer. Reconstitute with bacteriostatic water, refrigerate, and avoid repeated freeze-thaw; as a 29-residue peptide it is more fragile in solution than in powder form.
Plain-language explanations describe what researchers study — not what any product does for a person, and not medical advice. Every material here is sold for laboratory research use only and is not for human or animal use.
Studies cited
- Sermorelin: a better approach to management of adult-onset growth hormone insufficiency? (Clinical Interventions in Aging, 2006)
- Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency (BioDrugs, 1999)
- Advances in the detection of growth hormone releasing hormone synthetic analogs (Drug Testing and Analysis, 2021)
- A potentially effective drug for patients with recurrent glioma: sermorelin (Annals of Translational Medicine, 2021)
Questions
What is sermorelin?
A synthetic version of the first 29 amino acids of growth-hormone-releasing hormone — the fragment that carries the receptor activity. Supplied here as reference material for laboratory research only.
How does it differ from growth hormone?
It acts one step upstream. Rather than supplying the hormone, it signals the pituitary receptor that governs release, so the body's own pulsatility and feedback remain in the loop.
Was it ever an approved medicine?
Yes. It was developed and marketed pharmaceutically, notably for diagnosing and managing growth-hormone deficiency, and was later discontinued commercially.
How strong is the evidence?
Stronger than most compounds in this catalog for its original clinical setting. Evidence for uses beyond that — in ageing or performance contexts — is substantially weaker.
How is it stored and reconstituted?
Keep the lyophilized powder cold and dark; reconstitute with bacteriostatic water, refrigerate, and avoid repeated freeze-thaw cycles.
For laboratory research and educational purposes only. Not medical advice. The materials discussed are not for human or animal consumption and have not been evaluated by the FDA.